Skip to main content
All lobbying filings

MANATT, PHELPS, AND PHILLIPS

Lobbying for DENALI THERAPEUTICS · Biopharmaceutical Company

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2025 · California · $67,500.00 income · posted Jul 10, 2025

Official filing document

 Lobbying activity 1
Health Issues

Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem